Bronchodilating effect of oxitropium bromide in heart disease patients with exacerbations of COPD: double-blind, randomized, controlled study.

Anti-cholinergic agents are considered the bronchodilator therapy of first-choice in the treatment of patients with stable chronic obstructive pulmonary disease (COPD) associated with heart disease since they may be as effective or more effective than inhaled beta2-agonists and, moreover, they do not interact with cardiac beta-adrenoceptors. The aim of our study was to evaluate the bronchodilator activity of oxitropium bromide in outpatients suffering from exacerbations of COPD associated with heart diseases (ischaemic heart disease and/or arrhythmias). We recruited 50 consecutive outpatients (33 males and 17 females, mean age 68.6 years, 15 current smokers and 35 ex-smokers). Each patient performed body plethismography in basal condition and 30 min after inhalation of 200 microg metered dose inhaler (MDI) oxitropium bromide administered by a device (Fluspacer). FEV1, FVC, MMEF25-75, sRaw and tRaw were evaluated. Thirty minutes after 200 microg oxitropium bromide administration, we observed a significant improvement in FEV1 11.6% +/- 1 (mean +/- SEM) (P<0.01); FVC, MMEF25-75 sRaw variation was respectively: 9.2% +/- 0.6, 31.4 +/- 2.9, -19.9 +/- 1.1. Placebo did not significantly change pulmonary function. Our data suggest that oxitropium bromide bronchodilator activity is effective in exacerbations of COPD.

[1]  C. Rizzi.  Statistical Methods , 2020, Springer Theses.

[2]  R. Rodríguez-Roisín,et al.  Toward a consensus definition for COPD exacerbations. , 2000, Chest.

[3]  T. Self,et al.  Can We Justify Ipratropium Therapy as Initial Management of Acute Exacerbations of COPD? , 1999, Pharmacotherapy.

[4]  K. Nishimura,et al.  Pharmacological Treatment in Acute Exacerbations of Chronic Obstructive Pulmonary Disease , 1998, Drugs & aging.

[5]  D. Górecka.  Cardiac arrhythmias in chronic obstructive pulmonary disease. , 1997, Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace.

[6]  R. Cydulka,et al.  Effect of different albuterol dosing regimens in the treatment of acute exacerbation of chronic obstructive pulmonary disease. , 1997, Annals of emergency medicine.

[7]  B. Lipworth,et al.  Dose-Response of Inhaled Drugs in Asthma , 1997, Clinical pharmacokinetics.

[8]  J. Barberà,et al.  Ventilation-perfusion response after fenoterol in hypoxemic patients with stable COPD. , 1996, Chest.

[9]  A. Siefkin.  Optimal pharmacologic treatment of the critically ill patient with obstructive airways disease. , 1996, The American journal of medicine.

[10]  John L. Hankinson,et al.  Standardization of Spirometry, 1994 Update. American Thoracic Society. , 1995, American journal of respiratory and critical care medicine.

[11]  J C Yernault,et al.  Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. , 1995, The European respiratory journal.

[12]  P. Moayyedi,et al.  Comparison of nebulised salbutamol and ipratropium bromide with salbutamol alone in the treatment of chronic obstructive pulmonary disease. , 1995, Thorax.

[13]  P. Howard,et al.  The QTc interval, autonomic neuropathy and mortality in hypoxaemic COPD. , 1995, Respiratory medicine.

[14]  J. Dasta,et al.  Beta-Agonists in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease , 1994, The Annals of pharmacotherapy.

[15]  J. Varon,et al.  Acute exacerbations of obstructive lung disease. , 1994, Postgraduate medicine.

[16]  W. McIlroy,et al.  The effect of increasing doses of beta-agonists on airflow in patients with chronic airflow limitation. , 1993, Respiratory Medicine.

[17]  J. Yernault,et al.  Perceived effect on shortness of breath of an acute inhalation of saline or terbutaline: variability and sensitivity of a visual analogue scale in patients with asthma or COPD. , 1992, The European respiratory journal.

[18]  N. Pearce,et al.  Cardiovascular effects of fenoterol under conditions of hypoxaemia. , 1992, Thorax.

[19]  J. Karpel,et al.  A comparison of the effects of ipratropium bromide and metaproterenol sulfate in acute exacerbations of COPD. , 1990, Chest.

[20]  Robert J. Taylor,et al.  NEBULISED SALBUTAMOL WITH AND WITHOUT IPRATROPIUM BROMIDE IN ACUTE AIRFLOW OBSTRUCTION , 1989, The Lancet.

[21]  J. Montserrat,et al.  Effect of three different bronchodilators during an exacerbation of chronic obstructive pulmonary disease. , 1988, The European respiratory journal.

[22]  M. Newhouse,et al.  Aerosol therapy: nebulizer vs metered dose inhaler. , 1987, Chest.

[23]  P. Paré,et al.  Nebulized anticholinergic and sympathomimetic treatment of asthma and chronic obstructive airways disease in the emergency room. , 1987, The American journal of medicine.

[24]  O. Pahlm,et al.  Cardiac arrhythmias in patients with mild-to-moderate obstructive lung disease. Comparison of beta-agonist therapy alone and in combination with a xanthine derivative, enprofylline or theophylline. , 1985, Chest.

[25]  P. Hellstrom,et al.  Fenoterol and ipratropium bromide in respirator treatment of patients with chronic bronchitis , 1985 .

[26]  R E Brashear,et al.  Arrhythmias in patients with chronic obstructive pulmonary disease. , 1984, The Medical clinics of North America.

[27]  A Minette,et al.  Oxitropium bromide (Ba 253), an advance in the field of anticholinergic bronchodilating treatments. Preliminary results. , 1979, Revue de l'Institut d'hygiene des mines.

[28]  T. Petty,et al.  Arrhythmias associated with acute respiratory failure in patients with chronic airway obstruction. , 1973, Chest.